News
CYCC
1.530
-4.38%
-0.070
HTZ, CYCC and WORX among pre-market losers
On the Move HTZ, CYCC and WORX among pre-market losers. ReAlpha Tech Corp. (AIRE) and Boyd Gaming Corp (BYD) among losers. ACM Research announces preliminary unaudited revenue and shipments for the first quarter of 2024.
Seeking Alpha · 11h ago
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Caterpillar Inc. Fell 6.6% to $339.37 on Thursday. Caterpillar reported better-than-expected first-quarter EPS but missed revenue estimates. Barfresh Food Group, Inc. Shares surged 87.2% after the company reported better than expected results. Chicken Soup for the Entertainment for the Soul Entertainment dropped 75%.
Benzinga · 1d ago
CETX, ATNI and MNY among mid-day movers
On the Move CETX, ATNI and MNY among mid-day movers. Loar Holdings and Safe & Green Holdings Corp are among the Gainers. E-Home Household Service Holdings Ltd. Is one of the losers in the SA market.
Seeking Alpha · 1d ago
Cyclacel Pharmaceuticals Shares Hit All-Time Low on Planned Equity Sale
Cyclacel Pharmaceuticals says it plans to sell up to 5.95 million shares in a dilutive offering. Shares of the company hit an all-time low of $1.59, down 31%. The biopharmaceutical company's shares lost nearly a third of their value.
Dow Jones · 1d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Aclarion (NASDAQ:ACON) shares moved upwards by 66.7% to $0.48 during Thursday's regular session. Akso Health Group ( NASDAQ:AHG) shares increased by 29.87%. Processa Pharma (NASdaq:PCSA) stock increased by 43.18%. Cyclacel Pharmaceuticals stock declined by 33.1% during the session.
Benzinga · 1d ago
Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers
Healthcare On the Move: Mimedx Group, Cyclacel Pharmaceuticals, Predictive Oncology among healthcare movers. S&P 500 Health Care Sector -0.23% to 1637.36. Pharmaceuticals and Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 1d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Processa Pharma (NASDAQ:PCSA) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. Cyclacel Pharmaceuticals stock rose 23.04% and Compass Therapeutics shares rose 21.62%. Can Fite Biofarma (AMEX:CANF) stock also moved upwards.
Benzinga · 1d ago
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers. S&P 500 Health Care Sector -0.08% to 1644.11. Pharmaceuticals, Biotechnology & Life Science contributes 58% to the index.
Seeking Alpha · 2d ago
Weekly Report: what happened at CYCC last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at CYCC last week (0408-0412)?
Weekly Report · 04/15 10:50
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Eliem Therapeutics (NASDAQ:ELYM) stock moved upwards by 51.6% to $4.05 during Thursday's pre-market session. Rallybio stock increased by 49.07% and Alpine Immune Sciences stock rose 36.62% during the same period.
Benzinga · 04/11 12:10
Weekly Report: what happened at CYCC last week (0401-0405)?
Weekly Report · 04/08 10:54
Cyclacel Pharmaceuticals To Present New Clinical Data At 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential As A Precision Medicine For Cancer
New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma. Cyclacel Pharmaceuticals, Inc. Is a biopharmaceutical company developing innovative medicines based on cancer cell biology. New data from the CYC065-101 study will be presented at the American Society of Clinical Oncology in 2024.
Benzinga · 04/01 13:16
Weekly Report: what happened at CYCC last week (0325-0329)?
Weekly Report · 04/01 10:52
Cyclacel Pharma: General form for registration of securities under the Securities Act of 1933
Press release · 03/25 14:24
Weekly Report: what happened at CYCC last week (0318-0322)?
Weekly Report · 03/25 10:54
CYCC Stock Earnings: Cyclacel Pharmaceuticals Misses EPS for Q4 2023
Cyclacel Pharmaceuticals reported earnings per share of -$6.23. The company reported revenue of $31,000. This was below the analyst estimate for EPS of $5.89. The stock was down 2.7% after the market closed.
Investorplace · 03/20 00:53
Cyclacel Pharmaceuticals GAAP EPS of -$6.23 misses by $0.34
Cyclacel Pharmaceuticals' Q4 GAAP EPS of -$6.23 misses by $0.34. The company expects to have $6.3 million in cash and cash equivalents as of December 31, 2024. The Company expects to fund its planned programs through 2024.
Seeking Alpha · 03/19 20:15
*Cyclacel Pharmaceuticals: On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H24 >CYCC
Dow Jones · 03/19 20:10
*Cyclacel Pharmaceuticals 4Q EPS 0c >CYCC
Dow Jones · 03/19 20:09
More
Webull provides a variety of real-time CYCC stock news. You can receive the latest news about Cyclacel Pharma through multiple platforms. This information may help you make smarter investment decisions.
About CYCC
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.